The major focus of my lab is to understand how opioid receptors regulate chronic pain and headache disorders. We were the first group to develop a novel preclinical model of chronic migraine, which we used to identify the delta opioid receptor as a novel therapeutic target for this disorder.
We are CAPACITY Lab—an interdisciplinary team of scientists who build Community Academic Partnerships to Accelerate Community Implementation of Treatments for Youth.
The CLEAR Lab, led by Tory Eisenlohr-Moul, Ph.D., seeks to CLarify the Endocrinology of Acute Risk for emotional distress, interpersonal problems, substance abuse, and suicide attempts across the menstrual cycle in at-risk females. We seek to clarify the underlying pathophysiology of DSM-5 premenstrual dysphoric disorder, cyclical worsening of other psychiatric disorders, and perimenopausal mood symptoms. We use both mechanistic experimental trials and intensive observational studies in clinical samples, with the ultimate goal of predicting and preventing severe psychiatric outcomes.
The overarching goal of the Clinical Cognitive Affective Neuroscience (CCAN) lab is to increase our understanding of anxiety, depression, and mechanisms of treatment (e.g., Cognitive Behavioral Therapy) to reduce the suffering associated with these and other debilitating internalizing psychopathologies (e.g., stress-related disorders). Our methods include functional magnetic resonance imaging (fMRI), psychophysiological measures such as electroencephalogram (EEG), behavioral and subjective measures (e.g., neuropsychological, actigraphy, self-report) to advance our understanding of several interrelated themes.
The CAR lab examines cognitive and affective processes involved in the regulation of negative affect, in an effort to identify vulnerability factors for mood disorders.
The Crane Lab is interested in better understanding the brain and behavioral risk factors for Substance Use Disorder and co-occurring mental health disorders (e.g., depression, anxiety). Our lab uses multi-modal imaging techniques (fMRI and EEG), neuropsychological measures, self-report measures, and acute drug administration studies. The goal of our studies is to identify neurobehavioral risk factors that can be targeted for prevention strategies among individuals at risk for Substance Use Disorders and for treatment strategies among individuals diagnosed with Substance Use Disorders.